About Us
Precision. Personalization. Subtilitas.
Our Name. Our Mission.
Subtilitas comes from the Latin subtilis — meaning fine, precise, and discerning.
This philosophy defines everything we do. We bring refined precision to the design and execution of translational and clinical trials in dermatology and immunology, ensuring that every study captures the nuances that matter most.
We believe that every patient’s biology tells a unique story — and that precision medicine starts with understanding those subtle differences.
Through data-driven insights, specialized partners, and a deep understanding of individual biology, Subtilitas bridges scientific nuance with clinical impact, accelerating the development of personalized therapies for skin and immune diseases.
Industry Pioneers and Leaders
Tobin Dickerson, Ph.D.
Michael Howell, Ph.D.
Combined Experience
Over 25 years advancing non-invasive and precision platforms for skin sampling and biomarker discovery
Academic origins at Scripps Research and National Jewish Health introducing non-invasive sampling to enable translational research — now a standard in dermatology development
Industry pioneers in applying non-invasive platforms to dermatology clinical trials (first clinical program launched in 2013)
Comprehensive expertise spanning pre-clinical, translational, and clinical development, enabling seamless bench-to-bedside execution
Proven innovators with multiple patents in personalized medicine and biomarker-driven diagnostics
Differentiated leaders combining scientific rigor with industry-level precision and scalability